Production and commercialization of biopharmaceutical proteins with higher therapeutic efficacy have formed a progressive landscape that continues to push the growth of plant derived proteins market. A new Future Market Insights (FMI) report forecasts that the plant derived proteins market will experience a major upturn towards 2029, reaching a value of around US$ 185 Mn. Production of three main therapeutic protein classes, including antibodies, vaccines, and replacement proteins such as albumin, insulin, growth factors, and cytokines will remain industry’s prime focus area. Plant derived proteins are recognized as natural and environmentally-sustainable than microbial and mammalian cells. Owing to these benefits, there has been an increasing demand for such proteins from biopharmaceutical companies, as raw materials for therapeutic drug production, creating an absolute opportunity for growth of the plant derived proteins market.
Key Takeaways of Plant Derived Proteins Market Study
- The production of therapeutic proteins for disease treatment will gain traction, contributing more than 70% to global market revenues in 2029.
- Owing to low setup cost, transient plant expression systems (carrot or tobacco) remains preferred among protein manufacturers.
- Regenerative medicine-therapeutic agents continue to be the leading application area, on the back of their relatively cheap price point.
- Biopharmaceutical companies represent the leading consumer industry of plant derived proteins, with over 50% share in market throughout the forecast period.
- North America continues to lead, whereas East Asia holds the promise of lucrative opportunities, owing to several healthcare programs.
“Rising demand for passive immunization have led to development of new plant based platforms, which could transform and express recombinant therapeutic vaccines and antibodies more effectively with increased stability, high yield, and high quality,” says the FMI study.
Get Report Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11038
Acquisition Key Strategy Followed by Leading Market Players
Leading manufacturers in the plant derived proteins market are focusing on regional acquisition strategy to enhance their product portfolio and expand their regional presence. For instance, in 2017, Denka buys pharming pioneer Icon Genetics, which is a leading manufacturers of therapeutic proteins in plants. In 2014, Kentucky BioProcessing, Inc. was acquired by Reynolds American Inc., which is a wholly owned subsidiary of tobacco manufacturing company British American Tobacco plc.
Interested in more insights on the build-up of plant derived proteins market?
Plant derived proteins market, a new study from future market insights, opines on the production of plant derived proteins from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of; plant type (tobacco, carrot, rice, barley and others), protein type (industrial proteins & enzymes, therapeutic proteins cell culture functional proteins and others), application (regenerative medicine-therapeutic agents, regenerative medicine-functional material, cell culture application and others), platform (in-vitro culture system, whole plants and others) and end user (biopharmaceutical companies, academic & research institutes, contract research organization (CROS), contract manufacturing organization (CMOS)) across seven prominent regions.
Speak To Analyst For Queries about Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-11038
FREQUENTLY ASKED QUESTIONS ABOUT PLANT DERIVED PROTEINS MARKET
Will preference for natural and environmentally-sustainable proteins affects growth of the plant derived proteins market?
Recombinant protein production using plant platforms are gaining more acceptance among consumers owing to safety and efficacy of final product. The plant derived proteins market is growing and products are increasingly being used as therapeutic agents in cosmetics and skin care. In terms of usage in cosmetic applications, plant-derived proteins are recognized as more natural and environmentally-sustainable than microbial and mammalian cells.
How stringent regulations are hampering launch of new products?
In high-impact markets such as the U.S. and Europe, there are stringent regulations for the approval of plant-based technology platforms for commercial use. Also, prohibiting tobacco plant farming in certain European countries by government authorities, limits growth opportunities for the plant derived proteins market, especially among emerging players.
How will technological advancement convalesce the demand for plant derived proteins in near future?
Rapid production, ease of manipulation, low setup cost, high yield of proteins are some the advantages offered by commercial usage of transient expression. Owing to these advantages there is increasing demand for transient expression for production of recombinant pharmaceutical proteins, as it doesn’t require monitoring initial transformation problems.